
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Lexeo Therapeutics, Inc.

(Name of Issuer)

Common Stock, \$0.0001 par value per share

(Title of Class of Securities)

52886X107

(CUSIP Number)

05/28/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 52886X107

Names of Reporting Persons

1 Frazier Life Sciences Public Fund, L.P.

Check the appropriate box if a member of a Group (see instructions)

- 2 (a)
 (b)

3 Sec Use Only

Citizenship or Place of Organization

4 DELAWARE

Number of 5 Sole Voting Power
Shares

Beneficially Owned by Each Reporting Person With: 0.00
 Shared Voting Power
 6
 3,730,419.00
 Sole Dispositive Power
 7
 0.00
 Shared Dispositive Power
 8
 3,730,419.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9
 3,730,419.00
 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

 Percent of class represented by amount in row (9)

11
 6.8 %

12
 Type of Reporting Person (See Instructions)
 PN

Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of (i) 3,073,467 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. and (ii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

SCHEDULE 13G

CUSIP No. 52886X107

1
 Names of Reporting Persons
 FHMLSP, L.P.
 Check the appropriate box if a member of a Group (see instructions)

2
 (a)
 (b)

3
 Sec Use Only
 Citizenship or Place of Organization

4
 DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With: 5
 Sole Voting Power
 0.00
 Shared Voting Power
 6
 3,730,419.00
 Sole Dispositive Power
 7
 0.00

8 Shared Dispositive
Power

3,730,419.00

Aggregate Amount Beneficially Owned by Each Reporting Person

3,730,419.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)



Percent of class represented by amount in row (9)

6.8 %

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of (i) 3,073,467 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. and (ii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

SCHEDULE 13G

CUSIP No. 52886X107

Names of Reporting Persons

FHMLSP, L.L.C.

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

DELAWARE

Sole Voting Power

0.00

Shared Voting Power

3,730,419.00

Sole Dispositive Power

0.00

Shared Dispositive
Power

3,730,419.00

Aggregate Amount Beneficially Owned by Each Reporting Person

3,730,419.00

10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Percent of class represented by amount in row (9)

11 6.8 %

Type of Reporting Person (See Instructions)

12 OO

Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of (i) 3,073,467 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. and (ii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

SCHEDULE 13G

CUSIP No. 52886X107

Names of Reporting Persons

1 Frazier Life Sciences Public Overage Fund, L.P.

Check the appropriate box if a member of a Group (see instructions)

2 (a)
 (b)

3 Sec Use Only

Citizenship or Place of Organization

4 DELAWARE

Sole Voting Power

5 0.00

Number of Shares Beneficially Owned by Each Reporting Person With:

6 Shared Voting Power

818,607.00

Sole Dispositive Power

7 0.00

Shared Dispositive

8 Power

818,607.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9 818,607.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11 1.5 %

Type of Reporting Person (See Instructions)

12

Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of (i) 624,804 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P. and (ii) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P. The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

SCHEDULE 13G

CUSIP No. 52886X107

| | |
|---|---|
| 1 | Names of Reporting Persons |
| | FHMLSP Overage, L.P. |
| | Check the appropriate box if a member of a Group (see instructions) |
| 2 | <input type="checkbox"/> (a) |
| | <input type="checkbox"/> (b) |
| 3 | Sec Use Only |
| | Citizenship or Place of Organization |
| 4 | DELAWARE |
| | Sole Voting Power |
| 5 | 0.00 |
| Number of Shares Beneficially Owned by Each Reporting Person With: | Shared Voting Power |
| 6 | 818,607.00 |
| | Sole Dispositive Power |
| 7 | 0.00 |
| | Shared Dispositive Power |
| 8 | 818,607.00 |
| | Aggregate Amount Beneficially Owned by Each Reporting Person |
| 9 | 818,607.00 |
| | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) |
| 10 | <input type="checkbox"/> |
| | Percent of class represented by amount in row (9) |
| 11 | 1.5 % |
| | Type of Reporting Person (See Instructions) |
| 12 | PN |

Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of (i) 624,804 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P. and (ii) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the

members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P. The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

SCHEDULE 13G

CUSIP No. 52886X107

| | |
|---|---|
| 1 | Names of Reporting Persons |
| | FHMLSP Overage, L.L.C. |
| | Check the appropriate box if a member of a Group (see instructions) |
| 2 | <input type="checkbox"/> (a) |
| | <input type="checkbox"/> (b) |
| 3 | Sec Use Only |
| 4 | Citizenship or Place of Organization |
| | DELAWARE |
| | Sole Voting Power |
| 5 | 0.00 |
| Number of Shares Beneficially Owned by Each Reporting Person With: | Shared Voting Power |
| 6 | 818,607.00 |
| | Sole Dispositive Power |
| 7 | 0.00 |
| | Shared Dispositive Power |
| 8 | 818,607.00 |
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person |
| | 818,607.00 |
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) |
| | <input type="checkbox"/> |
| | Percent of class represented by amount in row (9) |
| 11 | 1.5 % |
| 12 | Type of Reporting Person (See Instructions) |
| | OO |

Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of (i) 624,804 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P. and (ii) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P. The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

SCHEDULE 13G

CUSIP No. 52886X107

1 Names of Reporting Persons
Frazier Life Sciences X, L.P.
Check the appropriate box if a member of a Group (see instructions)

2 (a)
 (b)

3 Sec Use Only
Citizenship or Place of Organization

4 DELAWARE

5 Sole Voting Power
0.00

Number of Shares Beneficially Owned by Each Reporting Person With:

6 Shared Voting Power
114,541.00

7 Sole Dispositive Power
0.00

8 Shared Dispositive Power
114,541.00

9 Aggregate Amount Beneficially Owned by Each Reporting Person
114,541.00

10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11 Percent of class represented by amount in row (9)
0.2 %

12 Type of Reporting Person (See Instructions)
PN

Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of (i) 87,424 shares of Common Stock held directly by Frazier Life Sciences X, L.P. and (ii) 27,117 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 27,117 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

SCHEDULE 13G

CUSIP No. 52886X107

Names of Reporting Persons

1

FHMLS X, L.P.

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

Sole Voting Power

5

0.00

Number of
Shares

Shared Voting Power

6

114,541.00

Beneficially
Owned by

Sole Dispositive Power

7

0.00

Reporting
Person

Shared Dispositive

With:

8 Power

8

114,541.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

114,541.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

0.2 %

Type of Reporting Person (See Instructions)

12

PN

Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of (i) 87,424 shares of Common Stock held directly by Frazier Life Sciences X, L.P. and (ii) 27,117 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 27,117 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

SCHEDULE 13G

CUSIP No. 52886X107

Names of Reporting Persons

1

FHMLS X, L.L.C.

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3 Sec Use Only
Citizenship or Place of Organization

4 DELAWARE

Sole Voting Power

5 0.00

Number of Shares Beneficially Owned by Each Reporting Person With:

6 114,541.00

Sole Dispositive Power

7 0.00

8 Shared Dispositive Power

114,541.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9 114,541.00

10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)



Percent of class represented by amount in row (9)

11 0.2 %

Type of Reporting Person (See Instructions)

12 OO

Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of (i) 87,424 shares of Common Stock held directly by Frazier Life Sciences X, L.P. and (ii) 27,117 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 27,117 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

SCHEDULE 13G

CUSIP No. 52886X107

Names of Reporting Persons

Frazier Life Sciences XI, L.P.

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

DELAWARE

Sole Voting Power

5 0.00

Number of Shares Beneficially Owned by

Each Reporting Person With: 6 Shared Voting Power
 304,989.00
 Sole Dispositive Power
 7
 0.00
 Shared Dispositive Power
 8
 304,989.00

9 Aggregate Amount Beneficially Owned by Each Reporting Person

304,989.00

10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Percent of class represented by amount in row (9)

11 0.6 %

Type of Reporting Person (See Instructions)

12 PN

Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of (i) 232,784 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. and (ii) 72,205 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 16, 2025. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P. The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 72,205 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

SCHEDULE 13G

CUSIP No. 52886X107

1 Names of Reporting Persons

FHMLS XI, L.P.

Check the appropriate box if a member of a Group (see instructions)

2 (a)

(b)

3 Sec Use Only

Citizenship or Place of Organization

4 DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With: 5 Sole Voting Power
 0.00
 Shared Voting Power
 6
 304,989.00
 Sole Dispositive Power
 7
 0.00
 8 Shared Dispositive Power

304,989.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

304,989.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

0.6 %

Type of Reporting Person (See Instructions)

12

PN

Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of (i) 232,784 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. and (ii) 72,205 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 16, 2025. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P. The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 72,205 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

SCHEDULE 13G

CUSIP No. 52886X107

Names of Reporting Persons

1

FHMLS XI, L.L.C.

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

Sole Voting Power

5

0.00

Number of
Shares

Shared Voting Power

Beneficially
Owned by

6

304,989.00

Each
Reporting

7

Sole Dispositive Power

Person
With:

7

0.00

Shared Dispositive

8

Power

304,989.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

304,989.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

0.6 %

Type of Reporting Person (See Instructions)

12

OO

Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of (i) 232,784 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. and (ii) 72,205 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 16, 2025. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P. The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 72,205 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

SCHEDULE 13G

CUSIP No. 52886X107

Names of Reporting Persons

1

Frazier Life Sciences XII, L.P.

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

Sole Voting Power

5

0.00

Number of Shares

Shared Voting Power

6

532,256.00

Beneficially Owned by

Sole Dispositive Power

Each Reporting Person

7

0.00

With:

Shared Dispositive

8

Power

532,256.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

532,256.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

1.0 %

Type of Reporting Person (See Instructions)

12

PN

Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of (i) 406,246 shares of Common Stock held directly by Frazier Life Sciences XII, L.P. and (ii) 126,010 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025. FHMLS XII, L.P. is the general partner of Frazier Life Sciences XII, L.P. and FHMLS XII, L.L.C. is the general partner of FHMLS XII, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XII, L.P. The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 126,010 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

SCHEDULE 13G

CUSIP No. 52886X107

| | |
|---|---|
| 1 | Names of Reporting Persons |
| | FHMLS XII, L.P. |
| | Check the appropriate box if a member of a Group (see instructions) |
| 2 | <input type="checkbox"/> (a) |
| | <input type="checkbox"/> (b) |
| 3 | Sec Use Only |
| 4 | Citizenship or Place of Organization |
| | DELAWARE |
| | Sole Voting Power |
| 5 | 0.00 |
| Number of Shares Beneficially Owned by Each Reporting Person With: | Shared Voting Power |
| 6 | 532,256.00 |
| | Sole Dispositive Power |
| 7 | 0.00 |
| | Shared Dispositive Power |
| 8 | 532,256.00 |
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person |
| | 532,256.00 |
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) |
| | <input type="checkbox"/> |
| 11 | Percent of class represented by amount in row (9) |
| | 1.0 % |
| 12 | Type of Reporting Person (See Instructions) |
| | PN |

Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of (i) 406,246 shares of Common Stock held directly by Frazier Life Sciences XII, L.P. and (ii) 126,010 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025. FHMLS XII, L.P. is the general partner of Frazier Life Sciences XII, L.P. and FHMLS XII, L.L.C. is the general partner of FHMLS XII, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XII, L.P. The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection

with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 126,010 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

SCHEDULE 13G

CUSIP No. 52886X107

Names of Reporting Persons

1

FHMLS XII, L.L.C.

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

Sole Voting Power

5

0.00

Number of
Shares

Shared Voting Power

Beneficially
Owned by
Each

6

532,256.00

Reporting
Person

7

0.00

With:

Shared Dispositive

8

Power

532,256.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

532,256.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

1.0 %

Type of Reporting Person (See Instructions)

12

OO

Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of (i) 406,246 shares of Common Stock held directly by Frazier Life Sciences XII, L.P. and (ii) 126,010 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025. FHMLS XII, L.P. is the general partner of Frazier Life Sciences XII, L.P. and FHMLS XII, L.L.C. is the general partner of FHMLS XII, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XII, L.P. The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 126,010 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

Names of Reporting Persons

1

James N. Topper

Check the appropriate box if a member of a Group (see instructions)

2

 (a) (b)

3

Sec Use Only

Citizenship or Place of Organization

4

UNITED STATES

Sole Voting Power

5

0.00

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:

Shared Voting Power

6

5,500,812.00

Sole Dispositive Power

7

0.00

Shared Dispositive

8

Power

5,500,812.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

5,500,812.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

9.9 %

Type of Reporting Person (See Instructions)

12

IN

Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of (i) 3,073,467 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., (ii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (iii) 624,804 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P., (iv) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (v) 87,424 shares of Common Stock held directly by Frazier Life Sciences X, L.P., (vi) 27,117 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (vii) 232,784 shares of Common Stock held directly by Frazier Life Sciences XI, L.P., (viii) 72,205 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (ix) 406,246 shares of Common Stock held directly by Frazier Life Sciences XII, L.P. and (x) 126,010 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P. FHMLS XII, L.P. is the general partner of Frazier Life Sciences XII, L.P. and FHMLS XII, L.L.C. is the general partner of FHMLS XII, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences

XII, L.P. The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025, (iii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (iv) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (v) 27,117 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (vi) 72,205 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, and (vii) 126,010 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

SCHEDULE 13G

CUSIP No. 52886X107

| | |
|---|---|
| 1 | Names of Reporting Persons |
| | Patrick J. Heron |
| | Check the appropriate box if a member of a Group (see instructions) |
| 2 | <input type="checkbox"/> (a) |
| | <input type="checkbox"/> (b) |
| 3 | Sec Use Only |
| 4 | Citizenship or Place of Organization |
| | UNITED STATES |
| | Sole Voting Power |
| 5 | 0.00 |
| Number of Shares Beneficially Owned by Each Reporting Person With: | Shared Voting Power |
| 6 | 5,500,812.00 |
| | Sole Dispositive Power |
| 7 | 0.00 |
| | Shared Dispositive Power |
| 8 | 5,500,812.00 |
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person |
| | 5,500,812.00 |
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) |
| | <input type="checkbox"/> |
| 11 | Percent of class represented by amount in row (9) |
| | 9.9 % |
| 12 | Type of Reporting Person (See Instructions) |
| | IN |

Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of (i) 3,073,467 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., (ii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (iii) 624,804 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P., (iv) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (v) 87,424 shares of Common Stock held directly by Frazier Life Sciences X, L.P., (vi) 27,117 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (vii) 232,784 shares of Common Stock held directly by Frazier Life Sciences XI, L.P., (viii) 72,205 shares of

Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (ix) 406,246 shares of Common Stock held directly by Frazier Life Sciences XII, L.P. and (x) 126,010 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P. FHMLS XII, L.P. is the general partner of Frazier Life Sciences XII, L.P. and FHMLS XII, L.L.C. is the general partner of FHMLS XII, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XII, L.P. The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025, (iii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (iv) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (v) 27,117 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (vi) 72,205 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, and (vii) 126,010 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

SCHEDULE 13G

CUSIP No. 52886X107

| | |
|---|---|
| 1 | Names of Reporting Persons |
| | Albert Cha |
| | Check the appropriate box if a member of a Group (see instructions) |
| 2 | <input type="checkbox"/> (a) |
| | <input type="checkbox"/> (b) |
| 3 | Sec Use Only |
| 4 | Citizenship or Place of Organization |
| | UNITED STATES |
| | Sole Voting Power |
| 5 | 0.00 |
| Number of Shares Beneficially Owned by Each Reporting Person With: | Shared Voting Power |
| 6 | 4,549,026.00 |
| | Sole Dispositive Power |
| 7 | 0.00 |
| | Shared Dispositive Power |
| 8 | 4,549,026.00 |
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person |
| | 4,549,026.00 |
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) |



Percent of class represented by amount in row (9)

11

8.3 %

Type of Reporting Person (See Instructions)

12

IN

Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of (i) 3,073,467 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., (ii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (iii) 624,804 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P., and (iv) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P. The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025, (iii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, and (iv) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

SCHEDULE 13G

CUSIP No. 52886X107

Names of Reporting Persons

1

James Brush

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

UNITED STATES

Sole Voting Power

5

0.00

Number of
Shares

Shared Voting Power

6

Beneficially
Owned by
Each

4,549,026.00

Sole Dispositive Power

7

Reporting
Person

0.00

With:

Shared Dispositive

8

Power

4,549,026.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

4,549,026.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)



Percent of class represented by amount in row (9)

11

8.3 %

Type of Reporting Person (See Instructions)

12

IN

Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of (i) 3,073,467 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., (ii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (iii) 624,804 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P., and (iv) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P. The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025, (iii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, and (iv) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

SCHEDULE 13G

CUSIP No. 52886X107

Names of Reporting Persons

1

Daniel Estes

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

UNITED STATES

Sole Voting Power

5

0.00

Number of
Shares

Shared Voting Power

6

Beneficially
Owned by
Each

837,245.00

Sole Dispositive Power

7

Reporting
Person

0.00

With:

Shared Dispositive

8

Power

837,245.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

837,245.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10



11 Percent of class represented by amount in row (9)

1.5 %

Type of Reporting Person (See Instructions)

12

IN

Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of (i) 232,784 shares of Common Stock held directly by Frazier Life Sciences XI, L.P., (ii) 72,205 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (iii) 406,246 shares of Common Stock held directly by Frazier Life Sciences XII, L.P. and (iv) 126,010 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P. FHMLS XII, L.P. is the general partner of Frazier Life Sciences XII, L.P. and FHMLS XII, L.L.C. is the general partner of FHMLS XII, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XII, L.P. The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025, (iii) 72,205 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, and (iv) 126,010 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

SCHEDULE 13G

Item 1.

Name of issuer:

(a)

Lexeo Therapeutics, Inc.

Address of issuer's principal executive offices:

(b)

345 PARK AVENUE SOUTH, FLOOR 6, NEW YORK, NY, 10010.

Item 2.

Name of person filing:

(a)

The entities and persons filing this statement (collectively, the "Reporting Persons") are: Frazier Life Sciences Public Fund, L.P. ("FLSPF") FHMLSP, L.P. FHMLSP, L.L.C. Frazier Life Sciences Public Overage Fund, L.P. ("FLSPOF") FHMLSP Overage, L.P. FHMLSP Overage, L.L.C. Frazier Life Sciences X, L.P. ("FLS X") FHMLS X, L.P. FHMLS X, L.L.C. Frazier Life Sciences XI, L.P. ("FLS XI") FHMLS XI, L.P. FHMLS XI, L.L.C. Frazier Life Sciences XII, L.P. ("FLS XII") FHMLS XII, L.P. FHMLS XII, L.L.C. James N. Topper ("Topper") Patrick J. Heron ("Heron") Albert Cha ("Cha") James Brush ("Brush") Daniel Estes ("Estes" and together with Topper, Heron, Cha and Brush, the "Members")

Address or principal business office or, if none, residence:

(b)

The address of the principal place of business for each of the Reporting Persons is: c/o Frazier Life Sciences Management, L.P. 1001 Page Mill Rd, Building 4, Suite B Palo Alto, CA 94304

Citizenship:

(c)

Entities: FLSPF - Delaware, U.S.A. FHMLSP, L.P. - Delaware, U.S.A. FHMLSP, L.L.C. - Delaware, U.S.A. FLSPOF - Delaware, U.S.A. FHMLSP Overage, L.P. - Delaware, U.S.A. FHMLSP Overage, L.L.C. - Delaware, U.S.A. FLS X - Delaware, U.S.A. FHMLS X, L.P. - Delaware, U.S.A. FHMLS X, L.L.C. - Delaware, U.S.A. FLS XI - Delaware, U.S.A. FHMLS XI, L.P. - Delaware, U.S.A. FHMLS XI, L.L.C. - Delaware, U.S.A. FLS XII - Delaware, U.S.A. FHMLS XII, L.P. - Delaware, U.S.A. FHMLS XII, L.L.C. - Delaware, U.S.A. Individuals: Topper - United States Citizen Heron - United States Citizen Cha - United States Citizen Brush - United States Citizen Estes - United States Citizen

Title of class of securities:

(d)

Common Stock, \$0.0001 par value per share

CUSIP No.:

(e)

52886X107

- Item 3. If this statement is filed pursuant to \hat{A} § \hat{A} 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
- (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
 - (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
 - (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
 - (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
 - (e) An investment adviser in accordance with \hat{A} § 240.13d-1(b)(1)(ii)(E);
 - (f) An employee benefit plan or endowment fund in accordance with \hat{A} § 240.13d-1(b)(1)(ii)(F);
 - (g) A parent holding company or control person in accordance with \hat{A} § 240.13d-1(b)(1)(ii)(G);
 - (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
 - (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
 - (j) A non-U.S. institution in accordance with \hat{A} § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with \hat{A} § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
 - (k) Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

Amount beneficially owned:

- (a) The information contained in row 9 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
Percent of class:
- (b) The information contained in row 11 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference. Due to field limitations of the EDGAR filing system, the percentages listed in Row 11 of Topper's and Heron's cover pages have been rounded down from 9.99% to 9.9%. %
- (c) Number of shares as to which the person has:
 - (i) Sole power to vote or to direct the vote:

The information contained in row 5 of each Reporting Person's cover page to this Schedule 13G is incorporated by reference.
 - (ii) Shared power to vote or to direct the vote:

The information contained in row 6 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
 - (iii) Sole power to dispose or to direct the disposition of:

The information contained in row 7 of each Reporting Person's cover page to this Schedule 13G is incorporated by reference.
 - (iv) Shared power to dispose or to direct the disposition of:

The information contained in row 8 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Frazier Life Sciences Public Fund, L.P.

Signature: /s/ Steve R. Bailey
By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP
Name/Title: of FHMLSP, L.P., GP of Frazier Life Sciences
Public Fund, L.P.
Date: 06/04/2025

FHMLSP, L.P.

Signature: /s/ Steve R. Bailey
By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP
Name/Title: of FHMLSP, L.P.
Date: 06/04/2025

FHMLSP, L.L.C.

Signature: /s/ Steve R. Bailey
Name/Title: By Steve R. Bailey, CFO of FHMLSP, L.L.C.
Date: 06/04/2025

Frazier Life Sciences Public Overage Fund, L.P.

Signature: /s/ Steve R. Bailey
By Steve R. Bailey, CFO of FHMLSP Overage,
Name/Title: L.L.C., GP of FHMLSP Overage, L.P., GP of
Frazier Life Sciences Public Overage Fund, L.P.
Date: 06/04/2025

FHMLSP Overage, L.P.

Signature: /s/ Steve R. Bailey
By Steve R. Bailey, CFO of FHMLSP Overage,
Name/Title: L.L.C., GP of FHMLSP Overage, L.P.
Date: 06/04/2025

FHMLSP Overage, L.L.C.

Signature: /s/ Steve R. Bailey
By Steve R. Bailey, CFO of FHMLSP Overage,
Name/Title: L.L.C.
Date: 06/04/2025

Frazier Life Sciences X, L.P.

Signature: /s/ Steve R. Bailey
By Steve R. Bailey, CFO of FHMLS X, L.L.C.,
Name/Title: GP of FHMLS X, L.P., GP of Frazier Life
Sciences X, L.P.
Date: 06/04/2025

FHMLS X, L.P.

Signature: /s/ Steve R. Bailey
By Steve R. Bailey, CFO of FHMLS X, L.L.C.,
Name/Title: GP of FHMLS X, L.P.
Date: 06/04/2025

FHMLS X, L.L.C.

Signature: /s/ Steve R. Bailey
Name/Title: By Steve R. Bailey, CFO of FHMLS X, L.L.C.
Date: 06/04/2025

Frazier Life Sciences XI, L.P.

Signature: /s/ Steve R. Bailey
By Steve R. Bailey, CFO of FHMLS XI, L.L.C.,
Name/Title: GP of FHMLS XI, L.P., GP of Frazier Life
Sciences XI, L.P.
Date: 06/04/2025

FHMLS XI, L.P.

Signature: /s/ Steve R. Bailey
By Steve R. Bailey, CFO of FHMLS XI, L.L.C.,
Name/Title: GP of FHMLS XI, L.P.
Date: 06/04/2025

FHMLS XI, L.L.C.

Signature: /s/ Steve R. Bailey
Name/Title: By Steve R. Bailey, CFO of FHMLS XI, L.L.C.
Date: 06/04/2025

Frazier Life Sciences XII, L.P.

Signature: /s/ Gordon Empey
By Gordon Empey, General Counsel of FHMLS
Name/Title: XII, L.L.C., GP of FHMLS XII, L.P., GP of
Frazier Life Sciences XII, L.P.
Date: 06/04/2025

FHMLS XII, L.P.

Signature: /s/ Gordon Empey
By Gordon Empey, General Counsel of FHMLS
Name/Title: XII, L.L.C., GP of FHMLS XII, L.P.
Date: 06/04/2025

FHMLS XII, L.L.C.

Signature: /s/ Gordon Empey
By Gordon Empey, General Counsel of FHMLS
Name/Title: XII, L.L.C.
Date: 06/04/2025

James N. Topper

Signature: /s/ Steve R. Bailey
By Steve R. Bailey, Attorney-in-Fact for James N.
Name/Title: Topper, pursuant to a Power of Attorney, a copy
of which was filed with the SEC on July 31, 2017
Date: 06/04/2025

Patrick J. Heron

Signature: /s/ Steve R. Bailey
By Steve R. Bailey, Attorney-in-Fact for Patrick J.
Name/Title: Heron, pursuant to a Power of Attorney, a copy of
which was filed with the SEC on July 31, 2017
Date: 06/04/2025

Albert Cha

Signature: /s/ Steve R. Bailey
By Steve R. Bailey, Attorney-in-Fact for Albert
Name/Title: Cha, pursuant to a Power of Attorney, a copy of
which was filed with the SEC on August 16, 2021

Date: 06/04/2025

James Brush

Signature: /s/ Steve R. Bailey

Name/Title: By Steve R. Bailey, Attorney-in-Fact for James Brush, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021

Date: 06/04/2025

Daniel Estes

Signature: /s/ Steve R. Bailey

Name/Title: By Steve R. Bailey, Attorney-in-Fact for Daniel Estes, pursuant to a Power of Attorney, a copy of which was filed with the SEC on April 18, 2022

Date: 06/04/2025

Exhibit Information

Exhibit 99.1 Joint Filing Agreement.

JOINT FILING AGREEMENT

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Common Stock of Lexeo Therapeutics, Inc.

Date: June 4, 2025

FRAZIER LIFE SCIENCES PUBLIC FUND, L.P.

By: FHMLSP, L.P., its General Partner

By: FHMLSP, L.L.C., its General Partner

By: /s/ Steve R. Bailey

Steve R. Bailey, Chief Financial Officer

Date: June 4, 2025

FHMLSP, L.P.

By: FHMLSP, L.L.C., its General Partner

By: /s/ Steve R. Bailey

Steve R. Bailey, Chief Financial Officer

Date: June 4, 2025

FHMLSP, L.L.C.By: /s/ Steve R. Bailey

Steve R. Bailey, Chief Financial Officer

Date: June 4, 2025

FRAZIER LIFE SCIENCES PUBLIC OVERAGE FUND, L.P.

By: FHMLSP Overage, L.P., its General Partner

By: FHMLSP Overage, L.L.C., its General Partner

By: /s/ Steve R. Bailey

Steve R. Bailey, Chief Financial Officer

Date: June 4, 2025

FHMLSP OVERAGE, L.P.

By: FHMLSP Overage, L.L.C., its General Partner

By: /s/ Steve R. Bailey

Steve R. Bailey, Chief Financial Officer

Date: June 4, 2025

FHMLSP OVERAGE, L.L.C.By: /s/ Steve R. Bailey

Steve R. Bailey, Chief Financial Officer

Date: June 4, 2025

FRAZIER LIFE SCIENCES X, L.P.

By: FHMLS X, L.P., its General Partner

By: FHMLS X, L.L.C., its General Partner

By: /s/ Steve R. Bailey

Steve R. Bailey, Chief Financial Officer

Date: June 4, 2025

FHMLS X, L.P.

By: FHMLS X, L.L.C., its General Partner

By: /s/ Steve R. Bailey

Steve R. Bailey, Chief Financial Officer

Date: June 4, 2025

FHMLS X, L.L.C.

By: /s/ Steve R. Bailey

Steve R. Bailey, Chief Financial Officer

Date: June 4, 2025

FRAZIER LIFE SCIENCES XI, L.P.

By: FHMLS XI, L.P., its General Partner

By: FHMLS XI, L.L.C., its General Partner

By: /s/ Steve R. Bailey

Steve R. Bailey, Chief Financial Officer

Date: June 4, 2025

FHMLS XI, L.P.

By: FHMLS XI, L.L.C., its General Partner

By: /s/ Steve R. Bailey

Steve R. Bailey, Chief Financial Officer

Date: June 4, 2025

FHMLS XI, L.L.C.

By: /s/ Steve R. Bailey

Steve R. Bailey, Chief Financial Officer

Date: June 4, 2025

FRAZIER LIFE SCIENCES XII, L.P.

By: FHMLS XII, L.P., its General Partner

By: FHMLS XII, L.L.C., its General Partner

By: /s/ Gordon Empey

Gordon Empey, General Counsel

Date: June 4, 2025

FHMLS XII, L.P.

By: FHMLS XII, L.L.C., its General Partner

By: /s/ Gordon Empey

Gordon Empey, General Counsel

Date: June 4, 2025

FHMLS XII, L.L.C.

By: /s/ Gordon Empey

Gordon Empey, General Counsel

Date: June 4, 2025

By: *

James N. Topper

Date: June 4, 2025

By: *

Date: June 4, 2025

By: **
Albert Cha

Date: June 4, 2025

By: **
James Brush

Date: June 4, 2025

By: ***
Daniel Estes

Date: June 4, 2025

By: /s/ Steve R. Bailey
Steve R. Bailey, as Attorney-in-Fact

* This Joint Filing Agreement was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017.

**This Joint Filing Agreement was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021.

***This Joint Filing Agreement was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on April 18, 2022.